Anderson Mehrle, MD
Cardiovascular Disease · Bartlesville, OKNPI 1396788022
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (39.1%), speaking fees and food and beverage — rather than concentrated in one kind of arrangement. 34 manufacturers reported payments, led by Shockwave Medical, Inc at 44.4% of the total. 2025 is the largest year on record at $55,303, more than ten times the $3,866 reported in 2019. Among cardiovascular disease clinicians in OK with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 477 payments — averaging $270.83 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Shockwave Medical, Inc$57K
- Johnson & Johnson$27K
- Abbott$15K
- Boston Scientific$15K
- Medtronic$5K
- Philips North America LLC$3K
- plus $7K from 28 others
Across 363 payments — averaging $4163.89 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Shockwave Medical, Inc$701K
- Abbott$301K
- Novartis$184K
- Janssen Research & Development, LLC$168K
- AstraZeneca$43K
- Vifor (international) Ltd.$38K
- plus $77K from 5 others
What the payments were for
- Consulting fees$50,48939%
- Speaking & faculty fees$45,64935%
- Travel & lodging$12,52510%
- Food & beverage$20,52316%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Shockwave Medical, Inc | 57 | $57,351 |
| Johnson & Johnson | 29 | $26,707 |
| Abbott | 46 | $15,375 |
| Boston Scientific | 37 | $14,770 |
| Medtronic(2 entities) | 99 | $5,200 |
| Philips North America LLC | 54 | $2,535 |
| Abiomed | 24 | $1,814 |
| Stryker | 12 | $1,583 |
| Inari Medical, Inc. | 13 | $605 |
| Endologix LLC | 3 | $502 |
| E.r. Squibb & Sons, L.L.C. | 29 | $419 |
| Pfizer | 26 | $418 |
| Novartis | 16 | $271 |
| Silk Road Medical, Inc. | 2 | $231 |
| Penumbra, Inc. | 2 | $204 |
| Inquis Medical, Inc. | 3 | $193 |
| Imperative Care, Inc | 2 | $180 |
| Innovation Technologies Inc | 2 | $129 |
| Veryan Medical Incorporated | 1 | $125 |
| Amgen | 2 | $115 |
| W. L. Gore & Associates, Inc. | 1 | $83 |
| Terumo Medical Corporation | 1 | $77 |
| AstraZeneca | 2 | $59 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 3 | $46 |
| Bayer | 2 | $31 |
| Asahi Intecc USA, Inc. | 1 | $31 |
| Novo Nordisk | 1 | $22 |
| Sanofi-aventis U.S. LLC | 1 | $21 |
| Irhythm Technologies, Inc. | 1 | $18 |
| Boehringer Ingelheim | 1 | $16 |
| Scpharmaceuticals Inc. | 1 | $15 |
| Merck | 1 | $14 |
| EKOS Corporation | 1 | $14 |
| Teleflex LLC | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter$54,474
- XARELTO$26,338
- GENERAL - THERAPIES$6,937
- Perclose ProGlide suture mediated closure system$4,000
- ABSOLUTE PRO$3,500
- Vascular Lithotripsy$2,549
- Emboshield NAV6 system$2,500
- XIENCE SIERRA$2,000
- ESPRIT$1,635
- Micra$1,431
- FLOWTRIEVER CATHETER, S$1,130
- CT THROMBECTOMY SYSTEM KIT$1,130
- Impella$1,012
- TYRX$682
- Torus Stent Graft System$361
- ENDOCROSS Device$361
- (4067) Tack Endo Sys BTK$341
- ARTIX MT$264
- ENROUTE Transcarotid Stent$143
- ENROUTE Transcarotid Neuroprotection System$143
How this compares
$129,185 in reported general payments places this provider in the 95th percentile of 164 cardiovascular disease providers in Oklahoma.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 238 | $237,811 |
| XareltoRivaroxaban | 228 | $195,220 |
| EntrestoSacubitril/Valsartan | 52 | $56,772 |
| BrilintaTicagrelor | 69 | $39,367 |
| JardianceEmpagliflozin | 33 | $28,397 |
| FarxigaDapagliflozin Propanediol | 22 | $20,619 |
| Repatha SyringeEvolocumab | 11 | $7,115 |
| Atorvastatin Calcium | 388 | $6,065 |
| ClopidogrelClopidogrel Bisulfate | 420 | $5,354 |
| Metoprolol Succinate | 346 | $4,541 |
| Ranolazine ErRanolazine | 55 | $2,759 |
| Rosuvastatin Calcium | 87 | $1,899 |
| Amlodipine Besylate | 241 | $1,824 |
| Potassium Chloride | 115 | $1,816 |
| Losartan Potassium | 158 | $1,603 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $418 | $237,811238 claims |
| Johnson & JohnsonXarelto | $26,707 | $195,220228 claims |
| AstraZenecaBrilinta, Farxiga | $59 | $59,98691 claims |
| NovartisEntresto | $271 | $56,77252 claims |
| Boehringer IngelheimJardiance | $16 | $28,39733 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 164 cardiovascular disease providers in Oklahoma.
Other cardiovascular disease in Bartlesville
- Kathryn FargusonBartlesville$7K
- Frank GaffneyTulsa$211K
- Aly El BanayosyOklahoma City$54K
- Dwight ReynoldsOklahoma City$47K
- Mohamad KhattabTulsa$47K
- Udho ThadaniOklahoma City$41K
- Steve KimTulsa$38K
- Robert SullivanOklahoma City$36K
- Eric AuerbachTulsa$35K
- Reji PappyOklahoma City$25K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.